VA Awards $23.9M Contract for In-Vitro Diagnostic Substances to Roche Diagnostics

Contract Overview

Contract Amount: $23,927 ($23.9K)

Contractor: Roche Diagnostics Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2026-04-11

End Date: 2027-04-10

Contract Duration: 364 days

Daily Burn Rate: $66/day

Competition Type: COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: REAGENTS

Place of Performance

Location: INDIANAPOLIS, MARION County, INDIANA, 46256

State: Indiana Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $23,926.7 to ROCHE DIAGNOSTICS CORPORATION for work described as: REAGENTS Key points: 1. Contract awarded to Roche Diagnostics Corporation for $23.9M. 2. The contract is for In-Vitro Diagnostic Substance Manufacturing. 3. Awarded by the Department of Veterans Affairs. 4. Contract duration is 364 days. 5. The contract was competed under SAP.

Value Assessment

Rating: good

The contract value of $23.9M for a 364-day duration appears reasonable given the specialized nature of in-vitro diagnostic substances. Benchmarking against similar, complex diagnostic material procurements would provide further validation.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

The contract was competed under SAP (Simplified Acquisition Procedures), suggesting a limited competition environment. While this can lead to faster procurement, it may not always yield the lowest possible price compared to full and open competition.

Taxpayer Impact: Taxpayer funds are being used for essential diagnostic substances for the VA. The pricing appears fair for the specialized nature of the products, but the limited competition warrants monitoring for long-term cost-effectiveness.

Public Impact

Ensures continued availability of critical diagnostic substances for VA healthcare facilities. Supports the operational needs of the Department of Veterans Affairs. Potential impact on patient care through timely access to diagnostic testing. Benefits Roche Diagnostics Corporation through a significant contract award.

Waste & Efficiency Indicators

Waste Risk Score: 66 / 10

Warning Flags

Limited competition under SAP
Potential for price increases in future renewals

Positive Signals

Ensures supply of critical medical materials
Awarded to a known supplier in the field

Sector Analysis

The healthcare sector, particularly in vitro diagnostics, relies on specialized manufacturing and stringent quality controls. Spending in this area is critical for patient care and disease management. Benchmarks for similar diagnostic substance contracts vary widely based on complexity and volume.

Small Business Impact

This contract was awarded to Roche Diagnostics Corporation, a large business. There is no indication of small business participation in this specific award, which is common for highly specialized manufacturing contracts.

Oversight & Accountability

The Department of Veterans Affairs is responsible for overseeing this contract to ensure timely delivery and quality of the in-vitro diagnostic substances. Standard contract management practices should be in place to monitor performance and adherence to terms.

Related Government Programs

In-Vitro Diagnostic Substance Manufacturing
Department of Veterans Affairs Contracting
Department of Veterans Affairs Programs

Risk Flags

Limited competition
Potential for price escalation
Supply chain vulnerability
Dependence on a single vendor

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $23,926.7 to ROCHE DIAGNOSTICS CORPORATION. REAGENTS

Who is the contractor on this award?

The obligated recipient is ROCHE DIAGNOSTICS CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $23,926.7.

What is the period of performance?

Start: 2026-04-11. End: 2027-04-10.

What is the specific breakdown of the $23.9M contract value across different types of diagnostic substances?

The provided data does not detail the specific breakdown of the $23.9M contract value. A more granular analysis would require access to the contract's line item details, which typically outline the quantities and unit prices for each type of in-vitro diagnostic substance being procured. This information is crucial for understanding the cost drivers and ensuring fair pricing across the product mix.

What are the risks associated with relying on a single supplier, even if competed under SAP, for critical diagnostic substances?

Relying on a single supplier, even through a competed SAP process, carries risks such as potential supply chain disruptions if the supplier faces production issues or geopolitical instability. It can also limit negotiation leverage for future contracts, potentially leading to higher costs over time. The VA should maintain awareness of alternative suppliers and market conditions.

How effectively does this contract support the VA's overall mission of providing healthcare to veterans?

This contract is highly effective in supporting the VA's mission by ensuring a consistent and reliable supply of essential in-vitro diagnostic substances. These substances are fundamental for accurate and timely medical diagnoses, enabling veterans to receive appropriate treatment and care. The continuity of supply directly impacts the quality and efficiency of healthcare services delivered by the VA.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Roche Holding AG

Address: 9115 HAGUE RD, INDIANAPOLIS, IN, 46256

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $23,927

Exercised Options: $23,927

Current Obligation: $23,927

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Parent Contract

Parent Award PIID: 36C26223A0039

IDV Type: BPA

Timeline